AGMB
Strong SellSinkerAgomAb Therapeutics NV · Healthcare · Belgium · $649M · Avg Vol: $2M/d
Sinker: Weak, expensive and falling. Nothing here to keep it afloat.
ABOUT AGOMAB THERAPEUTICS NV
Read
AgomAb Therapeutics NV is a clinical-stage biotechnology company focused on developing first-in-class therapeutic antibodies that activate the MERTK receptor to promote tissue repair and regeneration. The company’s innovative approach aims to address significant unmet medical needs in various fibrotic, inflammatory, and degenerative diseases. AgomAb holds a unique position in the biotech landscape by targeting natural regenerative pathways with its proprietary antibody platform.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -0.26 | -0.36 | -1.47 | -1.47 | — | -1.56 | -2.12 | -2.37 | — |
| Shares | 48.7M | 48.7M | 48.7M | 48.7M | 0.0% | 49.2M | — | — | — |
| Debt | 71.2K | 1.9M | 1.8M | 1.4M | 172.5% | 1.3M | — | — | — |
| Equity | 76.1M | 174.0M | 216.1M | 150.4M | 25.5% | — | — | — | — |
| Op CF | -21.8M | -28.3M | -53.8M | -59.5M | — | -65.1M | — | — | — |
| Inv CF | -51.2M | 46.0M | -0.8M | -37.9M | — | — | — | — | — |
| Fin CF | 43.2M | 91.1M | 111.2M | -0.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AGMB are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| AGMB | AgomAb Therapeutics NV(you) | $649M | 14 | Strong Sell |
| HYL.BR | Hyloris Pharmaceuticals SA | $143M | 14 | Strong Sell |
| TUB.BR | Financière de Tubize SA | $9.6B | 29 | Sell |
| LKFT | Lakefront Biotherapeutics NV | $1.9B | 68 | Buy |
| NYXH | Nyxoah SA | $163M | 10 | Strong Sell |
| MDXH | MDxHealth SA | $69M | 13 | Strong Sell |
| SEQUA.BR | Sequana Medical NV | $54M | 13 | Strong Sell |
| UCB.BR | UCB SA | $47.8B | 79 | Buy |
| IBAB.BR | Ion Beam Applications SA | $567M | 71 | Buy |
| FAGR.BR | Fagron NV | $1.9B | 83 | Strong Buy |
Peer medians: ROE 10.9% · P/E 18.4x · Gross margin 62.9%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.